BestAgeing - Südamehaiguste biomarkertte uuringute allianss paremaks südamehaigutse diagnoosimiseks vananevas Euroopa populatsioonis
The ageing of the European population represents a growing health care problem, threatening future economic growth and quality of life of our society. In particular, cardiovascular diseases show a marked increase with age and have remained the leading cause of morbidity and mortality in the elderly. Unfortunately, cardiovascular disorders and their associated risks are often difficult to diagnose in the elderly due to many age-related confounders and co-morbidities, leading to substantial uncertainties in diagnostic classification and therapeutic decision making with huge impact on patients' outcomes. Hence, there is an unmet need for novel biomarkers to enable a more accurate diagnosis, sub-classification, risk assessment, and treatment guidance for both acute and chronic cardiovascular diseases in the elderly. The BestAgeing consortium aims to improve this unsatisfactory situation by developing and validating novel omics-based biomarkers that may complement or substitute traditional biomarkers for more accurate or earlier diagnosis, better risk assessment, and appropriate guidance of therapies, overcoming limitations inherent with traditional biomarkers - supporting healthy ageing in Europe. Our study design addresses the most frequent and severe cardiovascular diseases of elderly patients by incorporating the appropriate disease and reference cohorts. Our strengths are our extensive previous work on biomarker identification and validation, our long-standing expertise in technology development and omics-based research, as well as our experience in translational research and test development as exemplified by the invention, the successful translation, and continuous refinement of cardiac Troponin T to a world-wide standard of good clinical practice. By combining leading experts in the field of "classical" biomarker development, high-throughput technologies, omics-biomarker research, research intensive SME and industry, and clinical institutions, we are confident that our efforts will generate novel European medical technologies that can improve the efficacy and efficiency of our care for elderly patients, which will also impact on the competiveness of research-intensive European industries and socioeconomic wealth in Europe.